Journey Medical Corp (DERM) Stock Price, Quote & News

Company Profile

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 480 434 6670

Website: journeymedicalcorp.com

Address:

9237 East Via de Ventura Boulevard, Suite 105, Scottsdale, United States

Deivittt Jul. 18 at 9:59 AM

$FBIO If you want to buy $DERM, it is interesting to do so through its parent company $FBIO since it is cheaper and they also give you the rest of the $FBIO drugs for free.

1 · Reply

Zellchair Jul. 17 at 6:14 PM

$FBIO $FBIOP Perfect trading range. Those who want to reduce or increase their risk can do so without further volatility. I have sold more FBIOP today, and bought a little more $DERM.

0 · Reply

MightyPumperDuck Jul. 17 at 4:04 PM

$DERM https://www.msn.com/en-us/money/companies/journey-medical-outlines-emrosi-launch-momentum-and-targets-expanded-payer-access-in-2025/ar-AA1EMYIM?ocid=BingNewsVerp

1 · Reply

MightyPumperDuck Jul. 17 at 4:03 PM

$DERM https://www.nasdaq.com/articles/journey-medical-corporation-reports-increase-payer-coverage-emrositm-65-commercial-lives

0 · Reply

Tomasini Jul. 17 at 4:02 PM

$DERM given emrosi is totally derisked from both fda, competition and now favorable insurance participation, this is an extremely low risk small cap bio as this sector goes. notbto mention no dilution risk and breakeven cas fliw from existing operations

0 · Reply

Zellchair Jul. 16 at 9:02 PM

$FBIO $FBIOP If I hadn't gone on a trip this morning (Swedish time), I would have written an updated view on Substack. I won't do it on my phone, so if there is an update, it will be at least 7-10 days away. Today's news was of course very disappointing and, for me/my opinion, also unexpected. At least as disappointing and worse that there has been no communication from Fortress. If there is no PR before opening tomorrow, I plan to sell more. I think you have to accept today's reaction that FBIOP will take more of a beating, considering how the CAEL-101 deal was structured with $19.6M directly to Fortress upon FDA approval, while FBIO is doing better when $DERM went up a bit. Unfortunately (for me), I think that trend will continue due to lower volume in FBIOP. Given that Fortress does not receive any milestones, royalties or annual dividends from DERM and Dotinurad and Triplex are years away, almost everything depends on CUTX-101 for reinvested dividends in the near term now.

3 · Reply

HumbleLearner69 Jul. 15 at 11:23 PM

$FBIO $FBIOP $DERM

0 · Reply

MightyPumperDuck Jul. 15 at 8:15 PM

$DERM No news allows the manipulation to occure. Glad to have bought a grip of shares yesterday. My last buy till earnings.

0 · Reply

cubsoxbull Jul. 15 at 8:10 PM

$DERM So we went from a high of $7.80 yesterday and now down 6% today. I just checked, short shares went from 550k on June 13th, now up to 984k on June 30th. I still don't understand why short selling is not illegal, but what do I know. Still think were sitting on a gold mine here. Good Luck to everyone.

0 · Reply

Sawnchey Jul. 15 at 7:52 PM

$DERM picked up a little more today, happy to gather all the sub-7 shares I can get my filthy hands on

0 · Reply

Market Cap	167.73M
Revenue (ttm)	56.13M
Net Income (ttm)	-14.67M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-26.14%
Debt to Equity Ratio	1.16

Volume	51,400
Avg Vol	143,646
Day's Range	N/A - N/A
Shares Out	23.30M
Stochastic %K	43%
Beta	0.80
Analysts	Strong Sell
Price Target	$9.75